Polydopamine coated multifunctional lanthanide theranostic agent for vascular malformation and tumor vessel imaging beyond 1500 nm and imaging-guided photothermal therapy.

The optical imaging guided tumor vessels and vascular malformation visualization by using the second near infrared emission beyond 1500 nm (NIR-II) is emerged as the next generation fluorescence imaging technique for early tumor diagnosis and identification of tumor-associated vascular features. On the other hand, developing theranostic probes for NIR-II imaging guided photothermal therapy (PTT) is of great significance, which is rarely explored. Herein, a high performance theranostic nanoplatform based on the core-shell structured NaLuF4 nanorods@polydopamine (denoted as NRs@PDA) by integrating the new advanced NIR-II imaging beyond 1500 nm with PTT function was developed for tumor-associated vascular malformation visualization and imaging-guided PTT.
Methods: In this work, the hydrophilic NaLuF4 NRs@PDA therapeutic probe was synthesized by using a reverse microemulsion method. The crystal phase, morphology, emission spectra and photothermal performance of the synthesized samples were systematically characterized. The NIR-II optical imaging and photothermal properties were investigated by in vitro and in vivo experiments.
Results: The NaLuF4 NRs@PDA therapeutic probe possessed efficient NIR-II emission centered at 1525 nm with high quantum yield (QY), good photo-stability and high biocompatibility. In vivo NIR-IIb imaging based on the designed probe can clearly visualize the whole-body vessel and brain vessel with high spatial resolution, especially tumor-associated vessels. In addition, in vitro and in vivo experiments also demonstrated that the designed NaLuF4 NRs@PDA probe possessed efficient photothermal conversion efficiency (40.18%) for PTT ablation of tumor.
Conclusion: With the excellent NIR-II imaging ability and PTT of tumor, the designed theranostic nanoplatform successfully realize the simultaneous tumor vessel diagnosis and tumor therapy, which may provide the opportunity of designing new theranostic bioprobes with combination of the NIR-II optical imaging technique and PTT function for tumor diagnosis and therapy.

Introduction

Recently, multifunctional nanoprobes combined features of imaging and therapeutic functions have received considerable attention due to the rapid development of nanotechnology in biomedicine 1-11. Among the general combination of imaging modalities (such as ultrasound imaging, magnetic resonance imaging, and fluorescence imaging) with therapy techniques (for example, PTT, photodynamic therapy, and chemotherapy), integrating optical imaging with PTT into a single nanoprobe has drawn immense attention for higher diagnosis requirement and enhanced therapeutic efficacy 12-16. Fluorescence imaging has provided a facile method to visualize complex biological processes at the molecular level and brain/tumor vascular 17, 18. In comparison with the conventional visible/NIR-I imaging, the new developed NIR-II imaging by utilizing the emission light in 1000-1700 nm has been considered as the next generation optical imaging technique with remarkable improvement in imaging sensitivity, and time/spatial resolution, owing to the significantly decreased photon scattering losses 19-22. Therefore, constructing NIR-II imaging-based nanotheranostic agent is significantly important.

So far, only a few fluorophores capable of emitting NIR-II luminescence, such as small organic fluorophores 23, 24, quantum dots (QDs) 25, 26, single-walled carbon nanotubes (SWNTs) 27, 28. Unfortunately, these small organic molecules retain in body too short to accumulate in diseased organs and tumor region, impeding their further applications in tumor detection and in vivo long-term studies 29, 30. Meanwhile, most of QDs composed of toxic elements, such as lead, mercury or arsenic 31-33, hindering their wide-spread application for in vivo bioimaging. Although, SWNTs have been developed as NIR-II imaging bioprobes, there are still several drawbacks, such as relatively low QY, uncontrollable size distributions (ranging from several to hundreds of nanometers), and broad-band emission peaks (>300 nm) 34, 35. These shortcomings ultimately inhibit their further applications in NIR-II imaging and size-dependent biodistribution study. Therefore, it is emergent to design efficient NIR-II imaging agent with narrow emission, controllable size and high QY. Recently, the lanthanide-based nanomaterials have been regarded as indispensable platforms for optical bioimaging due to the low photo-bleaching, low biotoxicity and high QY, and well-controlled size distribution 36-38. Therefore, development of lanthanide-based NIR-II imaging agent for theranostic nanoprobes is required.

On the other hand, PTT has been considered as a promising non-invasive therapy technology to current treatments of tumor 39-42. And, among the various photothermal agents (such as gold nanostructures, copper sulfide nanoparticles, and so on) 43-46, PDA derived from natural substances is considered as more promising PTT agent owing to the advantages of excellent biocompatibility, good biodegradability, and high photothermal conversion efficiency 47-50. Therefore, the development of efficient theranostic nanoprobe with combination of lanthanide-based NIR-II agent and PDA is extremely demanded.

Here, we have developed a core-shell structured NaLuF4: Gd/Yb/Er NRs@PDA as the integrative theranostic platform. The real-time optical bioimaging and imaging guided tumor detection based on the NRs@PDA were investigated in detail. Meanwhile, the through-skull non-invasive brain and abdomen vessel imaging without craniotomy was performed. In addition, non-invasive tumor vascular imaging was achieved. Apart from the NIR-II optical imaging, these NRs@PDA nanoprobes also possess high photothermal conversion efficiency, outstanding antitumor effect and excellent biocompatibility.

Results and Discussion

Structure characterization and optical properties of NaLuF4 NRs@PDA nanoprobes

Scheme presents the development of the core-shell structured NRs@PDA nanoprobes for NIR-II optical bioimaging/imaging-guided PTT application. And the shape and structure of the NRs@PDA nanoprobes were first characterized by transmission electron microscopy (TEM). As demonstrated in Figure and 1B, the rod-like morphology with high monodispersity and uniform size (average width and length of about 20 x 130 nm) was obtained. The high resolution TEM (HR-TEM) image displayed that the synthesized NaLuF4 NRs presented high crystalline nature (Figure ), and the d-spacing was measured to be about 1.93 Å, corresponding to the (210) lattice plane of the hexagonal phase NaLuF4. After PDA coated (Figure ), a thin PDA shell was successfully grown on the surface of the NaLuF4: Gd/Yb/Er NRs, indicating the formation of core-shell structure. And the scanning transmission electron microscope (STEM) image (Figure ) also demonstrated the presence of an uniform PDA outer shell (about 5 nm) on the surface of NaLuF4 NRs, further validating the core-shell structure. Figure shows the powder XRD of the synthesized NRs with and without PDA modification. As demonstrated, all of the characteristic diffraction peaks of NRs and NRs@PDA were matched well with the standard hexagonal phase structure (JCPDS: 16-0334). No other impurity peaks were detected, confirming the formation of the pure hexagonal phase structure. It should be noted that NaLnF4 host usually possesses two crystal phases including cubic and hexagonal and doping Gd3+ into NaLnF4 host has great influence on the crystal phase and size of NaLnF4 host. To reveal this, a comparison experiment with/without doping Gd3+ was performed. As shown in Figure the as-prepared NaLuF4: Yb/Er without doping Gd is composed of two typical structures including small cube and large rod. While doping 40% Gd, the sample only presents highly uniform rod-like structure. And the XRD analysis further demonstrates the as-prepared NaLuF4: Gd/Yb/Er nanocrystals exhibit pure hexagonal phase structure, indicating the Gd doping induced phase transformation from cubic to hexagonal. Furthermore, the X-ray photoelectron spectroscopy (XPS) analysis was performed. As demonstrated in Figure , after surface modification with PDA, besides the detection signals of Na, Lu, Gd, Yb and F, a new N element signal was obviously detected in NRs@PDA sample, further verifying the presence of PDA. Moreover, the Fourier transform infrared (FTIR) spectroscopy analysis was performed. As shown in Figure , the characteristic peaks centered at 1577 cm-1 and 1496 cm-1 of PDA were detected, further confirming the successful attachment of PDA on the surface of NaLuF4 NRs.

To reveal the effect of PDA on the optical properties of NRs, the upconversion (UC) and downconversion (DC, NIR-II region) spectra of the both NaLuF4 NRs and NRs@PDA excited by the 980 nm laser were studied. As demonstrated in Figure , after successful encapsulation of the PDA shell on NRs, the intensity of both green/red UC and NIR-II DC emission is decreased, which is mainly ascribed to the efficient fluorescence resonance energy transfer (FRET) from NRs to PDA owing to the overlap between the absorption band of PDA and the emission peaks of NRs 41, 42. However, it is worth noting that the red and NIR-II emissions of NRs@PDA are still strong, which fall in the “optical transparency window” with deeper penetration for excellent optical bioimaging. The green emission centered at 521/540 nm and the red emission centered at 650 nm were originated from the excited states 2H11/2, 4S3/2, and 4F9/2 to ground state 4I15/2 transition of Er3+, respectively (Figure ). The NIR-II emission at 1525 nm was ascribed to the electron transition from 4I13/2 to 4I15/2 of Er3+ 51. The NIR-II fluorescence QY of NRs@PDA in water was measured to be about 1.37 % using a standard IR-26 dye as reference (Figure ), which was higher than that of SWNTs (0.1~0.4 %) probes 52, 53. Moreover, the photo-stability curve and in vitro phantom bioimaging (Figure ) were performed, revealing the superior photo-stability of NaLuF4 NRs@PDA with a low photobleaching degree (0.96%) after 60 min irradiation, which was significantly lower than the previously reported small molecular probe 29. Additionally, compared with the indocyanine green (ICG), the synthesized NRs@PDA also presents superior photo-stability (Figure ). Therefore, it is expected that the NRs@PDA nanocomposites are promising probe for in vivo NIR-II optical bioimaging with high sensitivity.

NIR-II imaging-guided tumor vessel tracking

Prior to in vivo NIR-II bioimaging, the cytotoxicity of NaLuF4 NRs@PDA was evaluated by 3-(4, 5-dimethylthiazol-2-yl)-2-5-diphenyl-tetrazolium bromide (MTT) assay. As demonstrated in Figure , the cell viability was still maintained at above 87 % when treated with the high concentration (1 mg/mL) of the NRs@PDA, indicating the low cytotoxicity of NaLuF4 NRs@PDA. In view of the good biocompatibility and excellent NIR-II emission of NRs@PDA, in vivo NIR-II imaging of the anesthetized mouse intravenously injected with the NRs@PDA solution was performed by using 1525 nm emission. As shown in Figure and 2B, the time-dependent in vivo whole-body vessel imaging of lewis lung cancer (LLC) tumor-bearing and normal mouse was achieved. A strong NIR-II fluorescent signal from vessel can be detected at 30 s post-injection. And the signal in vessel decreased with increasing the post-injection time and almost disappeared after 20 min injection. It is noted that the distribution and size of the blood vessels are different in tumor-bearing and normal mice (marked with dashed box). The size of blood vessel in tumor-bearing mouse was bigger than that in normal mouse. To further reveal the difference, the corresponding zoom-in images of the chosen zones were demonstrated (Figure and 2E) and the intensity profiles along the line perpendicular to the tumor and normal vessel were shown in Figure and 2F. The vessel widths were evaluated based on the corresponding full width at half-maximum (FWHM) of the peaks according to the Gaussian fitting method. The vessel width obtained from tumor-bearing mouse (0.68 mm) was significantly larger than that of normal vessel (0.49 mm), suggesting the identification of the neovascular and detection of the abnormalities of blood vessels. And the time-dependent signal intensity changes in the heart and liver site of the tumor-bearing mouse were recorded. The signal in heart was decreased while the signal of liver was increased with prolonging injection time, indicating the real-time translocation of nanoprobes from systemic circulation to liver (Figure ). And the average fluorescence intensity ratio between the liver and tumor was evaluated to be 3.28 after 60 h injection (Figure ).

Additionally, ex vivo NIR-II optical bioimaging of the isolated organs (liver, heart, spleen, kidneys, and lung) harvested from the mouse were carried out under 980 nm laser excitation. As demonstrated in Figure , no obvious optical signal can be observed in heart and kidney, while bright NIR-II signal can be detected in both liver and spleen and dramatically decreased after 7 days injection, implying the main hepatic excretion route of NRs@PDA nanoprobes in living mouse. Moreover, the pharmacokinetic profiles (Figure ) of NaLuF4 NRs@PDA in living mouse were also evaluated by measuring the blood samples 54 at various time points and the half-life of this probe in blood circulation was measured to be ∼72 min. And the ex vivo imaging of the feces (Figure ) further demonstrated the main hepatic excretion of NRs@PDA nanoprobes. In addition, the high magnification NIR-II bioimaging of tumor site with field of view (FOV) of 26 mm × 21 mm was performed (Figure ). As shown in Figure , after intravenous injection with NRs@PDA solution, an obvious large-sized blood vessel connecting to the tumor site and abundant small vessels around and in the tumor site were clearly observed, which may provide necessary conditions for the tumor growth. The corresponding vessel widths along the colour lines marked in Figure were evaluated to be 304.42 μm (Figure ) and 120.19 μm (Figure ) by Gaussian-fitted method.

To further confirm the feasibility of NRs@PDA as optical bioprobes for tumor angiography and vascular abnormalities detection, the low and high magnification NIR-II vessel imaging of another kind of tumor-bearing mouse (colon cancer, HCT-116) were also performed. As shown in Figure and 3F, after intravenous injection with NRs@PDA solution, a single vessel with relative large size was detected and connected to the tumor tissue, further revealing the vascular anomaly for tumor growth. Moreover, the large amount of small vessels in tumor were also observed. And the corresponding vessel widths along the colour lines marked in Figure were evaluated to be 312.37, 115.25, 166.32, and 141.25 μm (Figure ) by Gaussian-fitted method. These findings reveal that the designed NIR-II emissive NRs@PDA are promising NIR-II emitter for whole-body vessel imaging, vascular malformation diagnosis and tumor vessel detection.

Non-invasive brain and abdomen vessel imaging

In vivo non-invasive brain vessel imaging with high spatial resolution has provided an indispensable way to diagnose the cerebral dysfunction or cerebrovascular diseases. The non-invasive NIR-II optical imaging of mouse's brain was performed by intravenous injection with 200 µL of NRs@PDA solution into an anesthetic nude mouse by a home-made in vivo imaging system equipped with InGaAs detector (NIRvanaTM Camera System, Princeton Instruments) under 980 nm laser excitation. As shown in Figure , the main venule vessels of the mouse brain can be obviously visualized. And the inferior cerebral vein, superior sagittal sinus, and transverse sinus depths (marked by 1, 2, and 3 in Figure ) under the scalp skin are also visualized. Moreover, many tiny capillary vessels can also be distinguished, indicating the high spatial resolution brain vessel imaging. Therefore, the synthesized NRs@PDA nanoprobes can be utilized as fluorescent agents for non-invasive cerebral vascular imaging through scalp and skull without craniotomy. To further study the vascular bifurcations, the intensity profiles of the vessels marked in Figure were studied. The corresponding zoom-in images of the chosen zones were exhibited in Figure and 4D. Due to the inevitable scattering and absorbance from the biotissues, the FWHM was used to represent the vessel's diameter. As demonstrated in Figure and 4F, the vessel widths were measured to be 45.15 and 85.45 μm. These results indicated that the designed NRs@PDA nanocomposites were ideal probes for brain blood vessel imaging.

To further test the feasibility of high resolution blood vessel imaging, the abdominal vessel imaging was also performed. As shown in the Supplementary Figure , the abdomen blood vessels were also identified with high resolution. Small vessels with diameters of 58.41 and 125.23 μm measured by the Gaussian-fitting method were achieved. These findings validate that our developed NRs@PDA nanocomposites are promising probes for non-invasive high spatial resolution blood vessel imaging.

In vitro photothermal performance and PTT of tumor

To reveal the potential ability of utilizing NRs@PDA in PTT application, we first measured the absorbance spectrum of the samples. As shown in Figure , the UV-Vis-NIR absorption spectrum of the NRs@PDA nanoprobes exhibits a broad absorbance from UV to NIR region, making it suitable for PTT application. Furthermore, concentration dependent temperature changes of NRs@PDA solutions were tested. As shown in Figure , compared with the ignored temperature increase of the pure water, the NRs@PDA solution (0.2 mg/mL) presents a remarkable temperature increase from 19.8 °C to 53.8 °C under the irradiation of 808 nm laser (3 W/cm2) for 600 s, which is also vividly visualized in photothermal pictures (Figure ). To further investigate the photothermal performance of the NRs@PDA nanoprobes, the power-dependent temperature changes (Figure ) of the NRs@PDA solutions were demonstrated. Moreover, the photothermal stability of the NRs@PDA nanoprobes was evaluated by four heating-cooling cycles (Figure ) through turning on/off laser, indicating the high photothermal-stability of the NRs@PDA nanoprobes. Photothermal conversion efficiency (η) of NRs@PDA nanocomposites was calculated to be 40.18% by using the fitting value of the cooling time versus negative natural logarithm data (Figure ), which was obtained from the cooling period curve in Figure The photothermal conversion efficiency was higher than that of Au nanorods (21%) 55 and Cu9S5 nanocrystals (25.7%) 56.

Due to the high photothermal performance of NRs@PDA nanoprobes in vitro, in vivo photothermal properties and PTT of tumor were studied. To demonstrate the thermal effect of NRs@PDA in vivo, mice were subcutaneously injected with phosphate buffer saline (PBS) and NRs@PDA and irradiated with 808 nm laser for 10 min. As shown in Figure , in contrast to the PBS group, the temperature of the mouse injected with NRs@PDA was significantly increased to ~55 °C. Therefore, the NRs@PDA nanoprobe could serve as an effective PTT agent for tumor ablation by irradiation with 808 nm laser. Then, the LLC tumor-bearing nude mice were used to evaluate the therapeutic efficacy. The tumor-bearing mice were randomly divided into four groups and treated with PBS, NRs@PDA, NIR irradiation (as control) and NRs@PDA + NIR irradiation. The tumor mice were treated with the 808 nm laser for 10 min every day. The change of tumor size was recorded after treatment (Figure and 6B). As demonstrated, the control groups showed rapid tumor growth and possessed large size, while mice treated with NRs@PDA and 808 nm laser irradiation presented remarkable inhibition of tumor growth, indicating the efficient tumor ablation by PTT. It is expected that the developed NRs@PDA nanoprobes with high photothermal conversion efficiency are promising theranostic agents for in vivo PTT of cancer.

Histological analysis

The bioprobes with excellent biocompatibility are highly demanded for biomedicine applications. The toxicity of NRs@PDA in living mouse was tested by a commonly used histological assessment method. Figure shows the histological analysis results of the main organs (heart, liver, spleen, lung and kidney) of treated groups and control group mouse stained with hematoxylin and eosin (H&E). No apparent lesions in the isolated organs were observed, indicating the good biocompatibility and negligible toxicity of the NRs@PDA for biomedical application.

Conclusions

In summary, the core-shell structured NaLuF4: Gd/Yb/Er NRs@PDA therapeutic agents composed of NIR-II emitting core with controlled size and high QY (1.37%) and photothermal shell of PDA were constructed. Non-invasive brain/abdomen vessel imaging with high spatial resolution (45.15 μm) was demonstrated by using this NIR-II bioprobe. More importantly, non-invasive vascular malformation/tumor vessel imaging was also achieved by using this NRs@PDA probe, indicating the obvious pathological changes of the blood vessels. Apart from the excellent NIR-II bioimaging, the designed NRs@PDA also can be used as highly efficient 808 nm laser-activated PTT agent according to the high photothermal conversion efficiency. And an efficient PTT of LLC tumor-bearing mouse was conducted, revealing the significant inhibition of tumor growth. Therefore, our findings pave the way of designing multifunction theranostic agents by combining the next generation NIR-II optical imaging and PTT into a single system for tumor vessel imaging and imaging-guided tumor ablation.

Methods

Chemicals and materials

All chemical reagents were obtained from the commercial institution and used without further purification. The rare earth (RE) chlorides including LuCl3•6H2O (99.9%), GdCl3•6H2O (99.9%), YbCl3•6H2O (99.9%), and ErCl3•6H2O (99.9%) were obtained from QingDa elaborate Chemical Reagent Co. Ltd (Shandong). NaOH, NaF, anhydrous alcohol, toluene, oleic acid (OA), IGEPAL CO-520, dopamine hydrochloride, ammonium hydroxide, 1,2-dichloroethane (DCE), IR-26 dye, cyclohexane, and other reagents were all purchased from Sinopharm Chemical Reagent Co., China.

Synthesis of NaLuF4: Yb/Er/Gd NRs

NaLuF4: 40%Gd/20%Yb/2%Er NRs were synthesized by a hydrothermal method. In a typical synthesis route 57, 1.2 g of NaOH was added in 2 mL deionized water with vigorously stirring. 10 mL of anhydrous alcohol and 20 mL of OA were then added to the above solution. A total of 1 mmol of RE (RE=Lu, Gd, Yb, Er) with a designed molar ratio and 8 mL of NaF (1 mol/L) solutions were added into the aforementioned solution under vigorously stirring. Subsequently, the obtained solution was transferred and sealed to a Teflon-lined stainless-steel autoclave after another 30 min stirring and heated at 190 °C for 24 h. The resulting precipitates were separated by centrifugation, washed with ethanol and water three times. The as-synthesized NRs were re-dispersed in cyclohexane and stored at 4 °C for further application.

Preparation of NaLuF4 NRs@PDA

In order to further multifunctional bioapplication, the hydrophilic NaLuF4: Gd/Yb/Er NRs@PDA was obtained by using a previously reported reverse microemulsion method 41. Typically, 1 g of IGEPAL CO-520 was added into 20 mL of cyclohexane solution containing with NaLuF4: Gd/Yb/Er NRs (30 mg) under vigorously stirred. The mixture was then stirred for 1h. Subsequently, 0.2 mL of ammonium hydroxide (28%) was slowly injected into solution and stirred for another 1 h. After that, 40 mg of dopamine hydrochloride was added into the above solution with ultrasonic treatment for 10 min. Keep the above solution further stirring for 24 h at room temperature and then the NRs@PDA was obtained. Finally the product was precipitated with ethanol and washed with water and ethanol three times. And then the NRs@PDA nanoprobes were re-dispersed in water for further use.

Characterization of NaLuF4 NRs and NRs@PDA

The crystal phase of the synthesized samples was characterized by utilizing a Rigaku D/max 2500 system X-ray diffractometer (XRD) with Cu-Kα radiation (λ = 1.54056 Å) operated at 40 kV and 250 mA. The morphology and size of the samples were characterized by TEM (FEI Tecnai F20) operated at 200 kV. The existed elements in the samples were further determined by XPS equipment (Thermo Fisher Scientific Escalab 250Xi). The FTIR of the surface ligands grafting on the NaLuF4 NRs was detected by a FTIR spectrometer (AVATAR370 FT-2R, Thermo Nicdet) at room temperature. Visible emission spectra of the samples were recorded via a Zolix Analytical Instrument (fluoroSENS 9000 A) and the down-shifting (NIR-II) fluorescence spectra were detected by using a NIR spectrometer (NIRQuest512, Ocean Optics) ranging from 900 to 1700 nm under the excitation of an external 980 nm laser. A UV-Vis-NIR spectrum was recorded with the absorption spectrometer (Lambda750, Perkin-Elmer) at room temperature.

Photothermal performance measurement of NRs@PDA

To illustrate the photothermal conversion performance of NRs@PDA naoprobes, 2 mL of tube containing with aqueous dispersion of NRs@PDA nanocomposites (0.15 mg/mL) was irradiated with 808 nm laser at 3 W cm-2 for 10 min and cooled down for 15 min. And, the temperature change curve was monitored by infrared thermal camera (Ti95, FLUKE). The photothermal conversion efficiency (η) of NRs@PDA was calculated according to the following formula 41:

where h represents the heat transfer coefficient, A denotes the surface area of the container, Tmax and Tsur are the equilibrium temperature and ambient temperature, respectively. Q0 represents the heat dissipation from the light absorbed by container, I is the incident laser power, and Aλ808 is the absorption intensity of NRs@PDA at 808 nm. The value of hA is derived according to the following equation:

where τS is the sample system time constant, mi and Cp,i are the mass and heat capacity of solvent, respectively. The Q0 is measured independently using sample cell containing pure water without sample. The value of τS is calculated by the cooling curve and following equation:

Quantum yield measurement

The fluorescence QY of the NaLuF4 NRs@PDA in water was calculated in a similar way to the reported method using a standard IR-26 dye (dissolved in DCE, QY = 0.5%) as a reference 58:

where Φ represents quantum yield, F denotes the integrated photoluminescence emission intensity, A denotes absorbance at the maximum excitation wavelength and n is the refractive index of the solvent (n = 1.44 for DCE, n = 1.33 for water, respectively). The subscripts s and r represent the sample and reference solutions, respectively.

Tumor animal models

8×106 Lewis lung cancer (LLC), and colon (HCT-116) cells were subcutaneously injected into nude mice with further culture to obtain the tumor-bearing mouse models for in vivo whole body vascular imaging of tumor mouse, high-magnification tumor vascular imaging and PTT therapy experiments. All animal procedures obeyed the Guidelines for the Care and Use of Laboratory Animals of Hunan Normal University and approved by the Animal Ethics Committee of Hunan Province.

In vitro cytotoxicity assay

The cytotoxicity of the NaLuF4 NRs@PDA was evaluated by using a MTT proliferation assay method. HeLa cells were cultured in a 96-well micro-plate at 37 °C under 5% CO2. Then, the cell culture medium in each well was added with different concentrations of NaLuF4 NRs@PDA (0, 100, 200, 400, 600, 800, 1000 µg/mL). Subsequently, the cells were incubated for another 24 h in the incubator. Then the cell viability was tested by the MTT method.

NIR-II optical bioimaging

The in vivo optical imaging of nude mouse based on NRs@PDA was captured by using a home-made small animal NIR-II bioimaging system (In Vivo Master, Wuhan Grand-imaging Technology Co., LTD) equipped with an InGaAs camera (Model: NIRvanaTM Camera System, Default Operating temperature: -80 °C, Princeton Instruments, 512 × 640 pixels) under the excitation of a 980 nm laser with a band pass filter (1400 -1600 nm) 59. All the whole body imaging in this work was detected by using a NIR-II lens (25 mm, Edmund Optics) with a field of view of 14.6 cm × 18.3 cm. The NRs@PDA (200 μL, 2 mg/mL) probes were intravenously injected into the mouse to acquire NIR-II real-time tracking images under the excitation of 980 nm laser (100 mW/cm2, 2 s). The ex-vivo bioimaging of the main organs (heart, lung, spleen, liver and kidney) harvested from the treated mice were performed with the same parameters to assess the biodistribution and accumulation of the NRs@ PDA in living mice. The digital picture of the tumor was taken by using a Canon digital camera.

The blood half-life time was tested based on the blood fluorescence intensity according to the previous report 54. The Kunming mice were first intravenously injected with NaLuF4 NRs@PDA (200 µL, 2 mg/mL), the blood samples were collected at time points from 1 min to 24 h. The content of the NaLuF4 NRs@PDA in blood was evaluated by recording the fluorescence intensity under the excitation of 980 nm laser with power density of 100 mW/cm2.

High magnification blood vessel imaging based on NRs@PDA in NIR-II region

The high magnification NIR-II blood vessel imaging of mouse brain, abdomen vein and tumor vessels was performed by using the same NIR-II bioimaging system (NIR-II lens: 100 mm, Edmund Optics, FOV: 21 mm × 26 mm, 512 × 640 pixels, 41 μm/pixel) by intravenously injecting with NRs@PDA solution into the anesthetized nude mice under the excitation of 980 nm laser (100 mW/cm2, 2s).

In vitro and in vivo PTT treatment of tumor mouse

For in vitro photothermal properties evaluation, the NaLuF4 NRs@PDA solutions with different concentrations (0, 0.05, 0.1, 0.2 mg/mL) were irradiated by NIR laser exposure (808 nm, 3 W/cm2) in 2 mL test tubes. And, the power-dependent temperature change of the NRs@PDA solution and the temperature change curves were also detected. In addition, the photothermal stability of the NRs@PDA solution was also investigated by continuous 10 min irradiation, cooling to room temperature, and followed by another 10 min irradiation for four cycles.

For in vivo photothermal evaluation, the normal mice were randomly divided into three groups (Group 1: subcutaneous injection with PBS (as control); Group 2: subcutaneous injection with PBS + 808 nm laser irradiation; Group 3: subcutaneous injection with NRs@PDA solution (0.2 mL, 0.2 mg/mL) + 808 nm laser irradiation). The in vivo temperature changes of the treated mice were recorded by FLUKE thermal camera under the 808 nm laser irradiation for 10 min. Then, the LLC tumor-bearing mice were divided to four groups for PTT experiments. And the tumor-bearing mice were treated with 808 nm laser irradiation for 10 min every day. The tumor sizes of each group were measured after post-treatment.

Histology analysis

To evaluate in vivo toxicity of NaLuF4 NRs@PDA, the histological tests of the major organs including heart, liver, spleen, lung and kidney with hematoxylin and eosin (H&E) staining obtained from the control and test (after 3 and 7 days of injection) groups were performed. The Kunming mice injected with 0.2 mL of NaLuF4 NRs@PDA (2 mg/mL) were denoted as the test group. The untreated mice were selected as control group.

Supplementary figures.

Click here for additional data file.